ClinicalTrials.gg
RecruitingNCT07576270Updated Sep 24, 2026

Effect of Resisted Deep Breathing and Myofascial Release in Postmastectomy

An interventional study of Resisted Deep Breathing and Myofascial release in Post Mastectomy Lymphedema, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to female participants aged 45 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2025, registered May 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
45 Years to 64 Years
Sex
Female
01

Study summary

This study aims to determine the combined effect of resisted deep breathing and Myofascial release on pain, respiratory efficiency, chest mobility and lymph edema in Postmastectomy.

Read the detailed description

The study will be randomized controlled trial and will conducted in Shokat Khanam hospital and Anmol cancer hospital. Non-probability convenience sampling technique will be used and 48 participants will be recruited in study after randomization. The subjects will be divided into two group. Group A will receive myofascial release. Group B will receive myofascial release with resisted deep breathing. Both Group will receive Baseline treatment which is including transcutaneous electrical nerve stimulation. The total duration of treatment will be 12 weeks and there will be 2 sessions each week. The tools that will be used are Numeric Pain Rating Scale (NPRS) for pain, Circumferential limb measurements for chest mobility or lymph edema and Spirometer for respiratory efficiency. After data collection will be analyzed by using SPSS version 21.

02

Conditions studied

  • Post Mastectomy Lymphedema

Keywords

  • Chest
  • Lymphedema
  • Post mastectomy
  • Myofasical release
  • Pain
03

In context

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 40 are open to participants now.

This study's planned enrollment of 48 is close to the median of 48 across 97 interventional studies indexed under Breast Cancer Lymphedema.

Browse Breast Cancer Lymphedema studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiation therapy and chemotherapy was finished at least three months
  • 6 months after mastectomy for breast cancer being diagnosed without lymphedema or with stage 1 lymphedema
  • Complete unilateral Mastectomy
  • pain and having one or more of the following symptoms: heaviness, numbness, oppression, stiffness, alterations in the function, or mobility of the limited shoulder range of motion.

Exclusion criteria

Exclusion Criteria:

  • Presence of shoulder pathologies for which surgical indications exist
  • Musculoskeletal injury in adjacent areas (shoulder or neck etc.)
  • bilateral surgery for the treatment of breast cancer
  • Bilateral lymphadenectomy
  • Open wounds on upper limbs
  • Circulatory disorders
  • History of shoulder surgery for reasons other than breast cancer.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Resisted Deep Breathing & Myofascial release

    Myofascial release is a hands-on therapy aimed at relieving pain and tightness in the fascia, the connective tissue surrounding muscles, by targeting trigger points and stiff areas and Resisted Deep Breathing (RDB) is a physiotherapy breathing technique used to improve respiratory muscle strength, lung expansion, and ventilation efficiency

    Other: Resisted Deep Breathing · Other: Myofascial release

  • Active comparator
    Myofascial release

    Myofascial release is a hands-on therapy aimed at relieving pain and tightness in the fascia, the connective tissue surrounding muscles, by targeting trigger points and stiff areas

    Other: Myofascial release

Interventions

  • OtherResisted Deep Breathing

    The total duration of treatment will be 12 weeks and there will be 2 sessions each week

  • OtherMyofascial release

    The total duration of treatment will be 12 weeks and there will be 2 sessions each week

06

What researchers measure

Primary outcomes

  1. Spirometer

    The evaluation of pulmonary function will be performed using conventional spirometry with a Spirobank USB spirometer (Medical International Research, Rome, Italy). The directly measured parameters will include lung volumes, capacities, and flow rates, assessed through the procedures of slow vital capacity (SVC), forced vital capacity (FVC), and maximal voluntary ventilation (MVV), performed in this order

    Time frame: 12th week

  2. Circumferential limb measurements

    In the proposed study, upper limb volume will be measured using circumference measurements. The anatomical positions of the arm will be selected at 7 cm intervals, including the wrist (the slenderest part), 7 cm above the wrist (lower arm), 7 cm below the elbow (lower arm), at the elbow, 7 cm above the elbow (upper arm), and at the same level as the axilla (upper arm). To minimize measurement error, all measurements will be taken at a constant pressure, with participants seated in a position where the hips and knees are bent at 90 degrees.

    Time frame: 12th week

  3. Numerical pain rating scale (NPRS)

    Subjective pain will be measured using the Numerical pain Rating Scale (NPRS), which is the simplest and most commonly used pain assessment tool. Patients will be asked to mark a point on a line ranging from 0 (no pain) to 10 (worst imaginable pain) to indicate their pain intensity.

    Time frame: 12th week

  4. Chest Mobility

    Chest circumference at maximal voluntary inspiration (insp) and maximal voluntary expiration (expir), as well as chest expansion (CE) calculated as the difference between insp and expir will be measured in a sitting position using a tape marked in 0.1 cm increments at the level of the fourth intercostal space. Participants will be instructed about the procedure and asked to exhale fully and hold for expir, and inhale deeply and hold for insp. The highest insp and lowest expir values from three attempts will be recorded, and their difference will represent chest expansion

    Time frame: 12th week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vijayakumar C, Jain A, Kalaranjani M, Kumbhar US, Kumar N, Sreenath GS. Effectiveness of Myofascial Release Compared to Manual Lymphatic Drainage in Reducing Post-Treatment Shoulder Pain and Stiffness Among Patients Who Underwent Breast Cancer Surgery and Adjuvant Radiotherapy: Randomised controlled trial. Sultan Qaboos Univ Med J. 2025 May 2;25(1):328-335. doi: 10.18295/2075-0528.2841. PubMed 40641717 ↗
  • Sun R, Liao Y. The impact of combined Gua Sha and myofascial release techniques on upper limb dysfunction in patients with breast cancer and axillary web syndrome: a prospective case series study. Support Care Cancer. 2025 Mar 12;33(4):270. doi: 10.1007/s00520-025-09259-2. PubMed 40072712 ↗
  • Lara-Palomo IC, Castro-Sanchez AM, Cordoba-Pelaez MM, Albornoz-Cabello M, Ortiz-Comino L. Effect of Myofascial Therapy on Pain and Functionality of the Upper Extremities in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2021 Apr 21;18(9):4420. doi: 10.3390/ijerph18094420. PubMed 33919315 ↗
  • Kim Y, Park EY, Lee H. The effect of myofascial release in patients with breast cancer-related lymphedema: a cross-over randomized controlled trial. Eur J Phys Rehabil Med. 2023 Feb;59(1):85-93. doi: 10.23736/S1973-9087.22.07698-5. Epub 2023 Jan 13. PubMed 36637800 ↗
  • AMANY RAW, FATMA SA, NANCY HA, ASHRAF EEJTMJoCU. Effect of Resisted Deep Breathing on Post Mastectomy Lymphedema. 2024;91(12):1443-8.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 66 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 12 months is below that.

Counting every sponsor, half of 69 studies reached it within 18 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07576270
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Oct 1, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 24, 2026

Study contacts

imran amjad
Contact
imran.amjad@riphah.edu.pk
03324390125
hina gul, PhD*
principal investigator · Riphah International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion